Speaking of in vitro diagnosis, the old shareholders know that this is the cradle of big bulls -
Dean, which went public in 2011, has nearly 25 times more than three years of growth; Lidman, which went public in 2012, has nearly five times the increase; Sannuo, which went public in March 2012, has risen nearly six times since its listing; Kehua Bio from 2005 The year 0.98 all the way up to 63.68 in June 2015, the year-on-year increase is over 60 times...
Since 2014, in vitro diagnosis has attracted a number of new members – Dyre Medical , Mike Bio, Meikang Bio, Runda Medical, and Wanfu Bio; today we will introduce the two in vitro diagnostic stocks in detail. Antu Bio, and the upcoming new shares of Haier Shi (delayed prospectus)
However, before introducing these two new members, the Dolphins would like to introduce the in vitro diagnostic industry that is still invigorating.
In vitro diagnosis is called "the doctor's eye" and refers to products that obtain clinical diagnosis information by detecting human body samples (various body fluids, cells, tissue samples, etc.) outside the human body, thereby judging disease or body function. service.
What is to be said here is that upstream key raw materials such as antigens and antibodies have been monopolized by foreign manufacturers.
In 2015, the global in vitro diagnostic market was approximately US$63.427 billion, and it is expected to grow steadily at a compound annual growth rate of 7% in the next three years. In 2015, China's diagnostic reagent market was about 21.6 billion yuan, currently accounting for only 6.56% of the global market share, while China's population accounts for nearly 20% of the world. It can be said that compared with developed countries, China's per capita in vitro diagnostic products consume very much. low. It is expected to maintain an average annual growth rate of 15% in the next three years. By 2016, China's in vitro diagnostic market will reach US$4.969 billion, making it the third largest market outside the US and the EU.
Among them, immunodiagnostic reagents and biochemical diagnostic reagents account for 33% and 27% of the in vitro diagnostic market share respectively. The combined market share of more than half is the main product in the in vitro diagnostic market in China. However, the development of biochemical diagnosis has been relatively mature, and the growth rate has been Slow down; and molecular diagnostic reagents are in the early stages of development.
New directions for industry development:
1. Chemiluminescent immunoreagent import substitution
In the technology of immunodiagnostic reagents, enzyme-linked immunoassay has the widest range of flux, rapid detection, simple operation and low cost. However, chemiluminescence immunoassay has the characteristics of high sensitivity, specificity, random and rapid operation, and is the future development. One of the important directions. At present, the chemical luminescence products are mainly from abroad, and the detection cost is high. It is an inevitable trend that domestic chemical luminescent products replace imports.
Industry Disposable Nitrile Gloves
We, Jiangsu YanFang Medical Technology Co., Ltd, commenced our medical gloves manufacturing in 2020. Currently, we possess a total of 12 high-capacity NBR Glove Dipping Production Lines.
Likewise, we are not only certified with ISO9001, ISO13485 but also fully complied with the essential USFDA, CE Compliances, as well as obtaining relevant accreditation of FDA510K, EN455, and EN374.
Nonetheless, our NBR Examination, Chemotherapy, and Food Grade products are being well established in both US and Europe markets.
We look forward to cooperating and working closely with our valuable customers and stakeholders, who are seeking long-term business relationships in high-quality NBR glove supplies.
Powder-free Nitrile Gloves,nitrile work gloves,safety nitrile gloves,disposable nitrile gloves,industrial gloves
Jiangsu Yanfang Medical Technology Co.,Ltd. , https://www.yanfangchina.com